StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Needham & Company LLC dropped their target price on OncoCyte from $9.00 to $4.25 and set a buy […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price objective on shares of OncoCyte from $9.00 to $4.25 and set a buy rating on the stock in a […]
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC lowered their price objective on OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a research report on Thursday, […]
Equities research analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the stock. Separately, Needham & Company LLC lowered their price objective on shares of OncoCyte from $9.00 to $4.25 and set a “buy” rating for […]